Oramed Pharmaceuticals Inc. ORMP
We take great care to ensure that the data presented and summarized in this overview for ORAMED PHARMACEUTICALS INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ORMP
View all-
Bml Capital Management, LLC Zionsville, IN2.19MShares$5.05 Million3.14% of portfolio
-
Murchinson Ltd. Toronto, A61.71MShares$3.95 Million1.22% of portfolio
-
Boothbay Fund Management, LLC New York, NY828KShares$1.91 Million0.06% of portfolio
-
Morgan Jess S & CO Inc366KShares$846,3862.07% of portfolio
-
Rathbones Group PLC Liverpool, X0290KShares$669,4440.0% of portfolio
-
David A. Siegel Two Sigma Advisers, LP | New York, Ny256KShares$590,4360.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny245KShares$566,6430.0% of portfolio
-
Bank Of America Corp Charlotte, NC172KShares$397,7630.0% of portfolio
-
Two Sigma Investments, LP New York, NY142KShares$327,2870.0% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA134KShares$310,4010.0% of portfolio
Latest Institutional Activity in ORMP
Top Purchases
Top Sells
About ORMP
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes. It is also developing ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes; and a weight loss treatment in the form of an oral leptin capsule. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in New York, New York.
Insider Transactions at ORMP
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 07
2024
|
Joshua Hexter COO & CBO |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+5.54%
|
-
|
|
Nov 07
2024
|
Miriam Kidron Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+3.64%
|
-
|
|
Nov 07
2024
|
Nadav Kidron President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
45,000
+2.41%
|
-
|
|
Nov 07
2024
|
Avraham Gabay Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+15.0%
|
-
|
|
Jun 21
2024
|
Avraham Gabay Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
140,040
+100.0%
|
-
|
|
Jun 06
2024
|
Yehuda Reznick Director |
BUY
Grant, award, or other acquisition
|
Direct |
760
+2.43%
|
-
|
|
Apr 17
2024
|
Yehuda Reznick Director |
BUY
Grant, award, or other acquisition
|
Direct |
29,800
+50.0%
|
-
|
|
Jan 30
2024
|
Daniel Aghion Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,750
+8.81%
|
-
|
|
Jan 04
2024
|
Joshua Hexter COO & CBO |
BUY
Grant, award, or other acquisition
|
Direct |
180,500
+27.25%
|
-
|
|
Jan 04
2024
|
Nadav Kidron President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
329,000
+15.59%
|
-
|
|
Jan 04
2024
|
Miriam Kidron Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
295,500
+27.9%
|
-
|
|
Jan 04
2024
|
Arie Mayer Director |
BUY
Grant, award, or other acquisition
|
Direct |
39,325
+17.26%
|
-
|
|
Jan 04
2024
|
Yadin Rozov Director |
BUY
Grant, award, or other acquisition
|
Direct |
38,820
+11.19%
|
-
|
|
Jan 04
2024
|
Leonard Sank Director |
BUY
Grant, award, or other acquisition
|
Direct |
39,325
+16.98%
|
-
|
|
Jan 04
2024
|
David Silberman Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
136,500
+27.14%
|
-
|
|
Jan 04
2024
|
Benjamin Shapiro Director |
BUY
Grant, award, or other acquisition
|
Direct |
35,070
+22.97%
|
-
|
|
Jan 04
2024
|
Daniel Aghion Director |
BUY
Grant, award, or other acquisition
|
Direct |
35,070
+31.32%
|
-
|
|
May 26
2023
|
David Silberman Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
24,500
+9.63%
|
-
|
|
May 26
2023
|
Joshua Hexter COO & CBO |
BUY
Grant, award, or other acquisition
|
Direct |
27,000
+8.22%
|
-
|
|
May 26
2023
|
Netanel Derovan Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,500
+12.06%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 1.44M shares |
|---|